Vertex Pharmaceuticals Inc (VRTX) — Analysis Summary
Vertex Pharmaceuticals Inc (VRTX) has a market cap of $138.78B with year-over-year revenue growth of +8.9%. Net margin stands at 32.9%. The stock trades at a P/E ratio of 31.5.
Key Takeaways
- Revenue changed +8.9% year-over-year
- Net margin of 32.9%
- P/E ratio of 31.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, VRTX posted revenue growth of +8.9% and trades at a P/E of 31.5.
Vertex Pharmaceuticals Inc (VRTX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
6,400
Headquarters
BOSTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.